A Swedish study found that 3D tomosynthesis screening detected 40% more cases of breast cancer compared with traditional digital mammography.
The appearance of bone metastases on FDG PET/CT was influenced by breast cancer histology, with non-FDG-avid lesions more common in invasive lobular carcinoma patients.
In a mouse model, researchers found that TRAIL-R2 inhibition prevented bone metastases, suggesting a possible therapeutic strategy for breast cancer patients.
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.
The risk of bone metastases from GISTs, though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases.
The US Food and Drug Administration has approved dinutuximab (Unituxin) for the treatment of high-risk neuroblastoma in pediatric patients.
The US Food and Drug Administration has approved filgrastim-sndz (Zarxio), a biosimilar of filgrastim (Neupogen), and the first such agent to be approved in the United States.
The FDA has approved nivolumab (Opdivo) for the treatment of metastatic squamous non-small-cell lung cancer (NSCLC) in patients who have progressed on a platinum-based chemotherapy.
The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.
A recent study found that radiation therapy was effective for the palliation of painful spinal metastases in patients with hepatocellular carcinoma.